ArticleClinical and experimental medicine2026
MDSC subpopulation dynamics predict disease evolution: a multidimensional biomarker framework for risk assessment in MDS.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To delineate subtype-specific associations of myeloid-derived suppressor cells (MDSCs) with tumor burden dynamics, leukemic progenitor features, and immunophenotypic remodeling in myelodysplastic syndromes (MDS), addressing unmet needs in prognostic biomarker discovery. In this cohort study of 70 MDS patients and 10 age-matched healthy controls, we performed multicolor flow cytometry to quantify monocytic (M-MDSC), early (e-MDSC), and granulocytic (G-MDSC) subsets alongside lymphocyte subpopulations (CD19 + B cells, CD3 + T cells, CD56 + NK cells). WT1 transcript levels were assessed via RQ-PCR, with tumor burden stratified by CD34 + blast percentage and IPSS-R criteria. Subtype-specific analysis revealed selective enrichment of monocytic MDSC (M-MDSC) in patients including elevated WT1 transcript levels, and elevated CD34 + cell proportions. Reduced baseline e-MDSC levels (< 2.36%) correlated with prolonged median overall survival (6.5vs4months; P = 0.0174). Notably, granulocytic MDSC (G-MDSC) demonstrated modest diagnostic utility (AUC = 0.7350, P = 0.0167) but failed to stratify patients by IPSS-R risk categories. Mechanistically, MDSC subsets exhibited distinct lymphoid interaction patterns: M-MDSC expansion demonstrated a positive correlation with CD19 + B-cell frequencies (r = 0.3051, P = 0.0102), while e-MDSC accumulation positively correlated with NK cells (r = 0.37, P = 0.001) and inversely correlated with T cells (r=-0.2845, P = 0.0170). M-MDSC and e-MDSC—but not G-MDSC—serve as clinically actionable biomarkers reflecting tumor burden and survival outcomes in MDS. Their distinct interactions with B, T, and NK lymphocytes implicate subset-specific immunosuppressive pathways, offering novel targets for risk-adapted immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.